tiprankstipranks
The Fly

Allarity granted EPO for DRP companion diagnostic for stenoparib

Allarity granted EPO for DRP companion diagnostic for stenoparib

Allarity (ALLR) Therapeutics announced that the European Patent Office, EPO, has issued a formal notice of its intention to grant a patent for Allarity’s Drug Response Predictor, DRP, companion diagnostic specific to stenoparib, the Company’s dual-targeted PARP/Tankyrase inhibitor. This patent represents a significant step forward in securing Allarity’s market position for stenoparib and the Stenoparib DRP companion diagnostic, which identifies patients most likely to derive clinical benefit from stenoparib treatment.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com